Pain
Conditions
Keywords
Anesthetics, Intravenous
Brief summary
The objective of this study is to compare the effectiveness and of perioperative use of Caldolor alone and in combination with OFIRMEV in total knee or hip arthroplasty procedures.
Detailed description
Patients undergoing total knee or hip arthroplasty procedures at University Pain Institute at Hahnemann will be included in this study. Following Institutional Review Board's approval, eligible patients will be selected from the Pre Admission Testing for total knee or hip arthroplasty surgeries planned at Hahnemann University Hospital. The cases will be randomized in a 1:1 ratio into either Group 1 or Group 2. Group 1 will receive 800 mg Caldolor at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total up to 120 hours (5 days) Group 2 will receive 800 mg Caldolor at the induction of anesthesia and 1000 mg Ofirmev at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge or for a total up to 120 hours (5 days) After the surgery, at the request of the patient they could receive morphine administered by patient-controlled analgesia pump, or by hospital staff. The analgesics and procedures involved in this study are all standard of care drugs prescribed and administered by the attending anesthesiologist for control of total knee or hip arthroplasty surgery related pain. Data collected for every patient will exist in the patient's medical chart as part of their standard medical care. No additional patient procedures or activities are mandated by this study. The data collection and analysis will be completed in duration of 1 year
Interventions
DRUGOfirmev
Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
DRUGCaldolor
Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
Sponsors
Cumberland Pharmaceuticals
Anita Gupta
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients age 18-70 scheduled for total knee or hip arthroplasty surgery * American Society of Anesthesiology physical status I, II, III
Exclusion criteria
* Impaired liver function * History of substance abuse or chronic pain * Patients known to be hypersensitive to any of the components of Caldolor or Ofirmev * Patients less than 18 years of age. * Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board \[IRB\]) and agree to abide by the study restrictions. * Be pregnant or nursing * Be otherwise unsuitable for the study, in the opinion of the Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analog Score (VAS) | Before surgery to Post-operative Day 5 (or Hospital Discharge) | First Post-op 100mm VAS pain score at rest and with movement |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Recovery (QoR40 scale) | Post-operative Day one | Patient satisfaction score |
Other
| Measure | Time frame | Description |
|---|---|---|
| Side effects | Post-operative Day one to five (or hospital discharge) | Incidence of opioid-related side effects |
Countries
United States
Outcome results
None listed